Literature DB >> 16781743

Steroidogenic alterations and adrenal androgen excess in PCOS.

Suhail A R Doi1, Mona Al-Zaid, Philip A Towers, Christopher J Scott, Kamal A S Al-Shoumer.   

Abstract

BACKGROUND: This cross-sectional study was undertaken to improve our understanding of the steroidogenic alterations leading to adrenal hyperandrogenism in polycystic ovarian syndrome (PCOS).
METHODS: Two-hundred and thirty-four women with clinical and biochemical features suggestive of PCOS underwent metabolic and hormonal evaluation. We used the androstenedione/DHEAS ratio as a surrogate for the level of ovarian 3betaHSD activity. We then selected the 90th percentile for the ratio in those with elevated DHEAS (>9 micromol/l) as the cut-off level beyond which excess DHEAS production will be minimized by excess ovarian 3betaHSD activity. This cut-off level was at a ratio of 1.5 and all PCOS women were then divided into two groups, the higher (>1.5) being the group with excess ovarian 3betaHSD activity. We hypothesized that women with a high ratio would be unlikely to have DHEAS excess due to the rapid conversion of DHEA to androstenedione. Those with a low ratio (concordant ovarian and adrenal steroidogenesis) could then either have high DHEAS or normal DHEAS, depending on whether CYP17 activity was higher or lower respectively.
RESULTS: Insulin resistance was found to be associated with decreased CYP17 activity while irregular cycles and neuroendocrine dysfunction were determined to be associated with higher ovarian 3betaHSD activity.
CONCLUSION: Adrenal androgen excess in PCOS seems to be related to insulin sensitivity as well as decreased activity of 3betaHSD, the latter being preferentially present in those women with regular cycles or without neuroendocrine dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781743     DOI: 10.1016/j.steroids.2006.05.005

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  14 in total

Review 1.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

2.  Alternative splicing of the androgen receptor in polycystic ovary syndrome.

Authors:  Fangfang Wang; Jiexue Pan; Ye Liu; Qing Meng; Pingping Lv; Fan Qu; Guo-Lian Ding; Christian Klausen; Peter C K Leung; Hsiao Chang Chan; Weimiao Yao; Cai-Yun Zhou; Biwei Shi; Junyu Zhang; Jianzhong Sheng; Hefeng Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

3.  A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.

Authors:  Fan Qu; Fang-Fang Wang; Rong Yin; Guo-Lian Ding; Mohamed El-Prince; Qian Gao; Bi-Wei Shi; Hui-Hui Pan; Yi-Ting Huang; Min Jin; Peter C K Leung; Jian-Zhong Sheng; He-Feng Huang
Journal:  J Mol Med (Berl)       Date:  2012-02-21       Impact factor: 4.599

Review 4.  Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome.

Authors:  Márcia Marly Winck Yamamoto; Sebastião Freitas de Medeiros
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

5.  Transcutaneous electrical acupoint stimulation alleviates the hyperandrogenism of polycystic ovarian syndrome rats by regulating the expression of P450arom and CTGF in the ovaries.

Authors:  Fan Qu; Yi Liang; Jue Zhou; Rui-Jie Ma; Jie Zhou; Fang-Fang Wang; Yan Wu; Jian-Qiao Fang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 6.  Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome.

Authors:  David H Abbott; Rao Zhou; Ian M Bird; Daniel A Dumesic; Alan J Conley
Journal:  Endocr Dev       Date:  2008

7.  The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome.

Authors:  A Michael Wallace; Naveed Sattar
Journal:  Clin Biochem Rev       Date:  2007-08

8.  Effect of Aloe barbadensis Mill. formulation on Letrozole induced polycystic ovarian syndrome rat model.

Authors:  Radha Maharjan; Padamnabhi S Nagar; Laxmipriya Nampoothiri
Journal:  J Ayurveda Integr Med       Date:  2010-10

9.  Evaluation of relationship between serum levels of anti-müllerian hormone, androgen, and insulin resistant with retrieval oocytes in overweight patients with polycystic ovary syndrome.

Authors:  Esmat Aghadavod; Nosratollah Zarghami; Laya Farzadi; Mina Zare; Abolfazl Barzegari; Ali Akbar Movassaghpour; Mohammad Nouri
Journal:  Adv Biomed Res       Date:  2015-03-25

10.  Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.

Authors:  Elisabeth Lerchbaum; Verena Schwetz; Thomas Rabe; Albrecht Giuliani; Barbara Obermayer-Pietsch
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.